PBYI Filings — Puma Biotechnology, Inc. - FilingSpy
PBYI
Puma Biotechnology, Inc.
A biopharmaceutical company based in Los Angeles that develops and sells cancer treatments, best known for its breast-cancer drug Nerlynx, a pill given to adults with HER2-positive breast cancer to help stop the disease from returning. It was founded in 2010 by Alan Auerbach, the same entrepreneur behind the earlier Cougar Biotechnology, whose big-cat naming theme it kept: puma and cougar are simply two names for the same mountain lion, and the drug itself was licensed from Pfizer in 2011.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -154.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.